Multicentric reticulohistiocytosis: the Mayo Clinic experience (1980–2017). (19th November 2019)

• Record Type: Journal Article
• Authors: Sanchez-Alvarez, Catalina; Sandhu, Avneek Singh; Crowson, Cynthia S; Wetter, David A; McKenzie, Gavin A; Lehman, Julia S; Makol, Ashima
• Is Part Of: Rheumatology. Volume 59:Number 8(2020)
• Page Start: 1898
• Page End: 1905
• Publication Date: 2019-11-19
• Subjects: multicentric reticulohistiocytosis -- MRH -- arthritis mutilans -- histiocytic disorder -- arthritis; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/kez555
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objectives: Multicentric reticulohistiocytosis (MRH), a rare histiocytic disease that can mimic other rheumatic conditions, may be associated with cancer and other autoimmune disorders. To better understand the disorder and its other associations, we aimed to evaluate clinical correlates and outcomes of all patients with MRH seen at Mayo Clinic, Rochester between 1980 and 2017. Methods: A retrospective medical record review was conducted to identify all patients with MRH between 1 January 1980 and 30 April 2017. Results: We identified 24 patients with biopsy-proven MRH (58% female, 75% Caucasian, median age at diagnosis 52 years, median follow-up of 2.3 years). All patients had cutaneous and articular involvement; 23 (96%) patients had papulonodular skin lesions (87% periungual and dorsal hand) and seven (30%) mucosal nodules; and 22 (92%) patients had arthralgias, 21 (88%) joint effusions and 13 (54%) synovitis. Most frequently used therapies included corticosteroids, cyclophosphamide, methotrexate and bisphosphonates. Biologics were used in four patients. Nine patients had symptomatic resolution at 1 year and 12 partial improvement. Radiological findings included erosive changes in three (60%) patients and arthritis mutilans in two patients (40%). Twenty-nine per cent of patients had a concomitant autoimmune disease and 25% malignancy including melanoma, endometrial, peritoneal and lung carcinoma. The 5-year survival rate was 85% (95% CI: 74, 100%). Conclusion: To our knowledge, this is the largest single-centre series of patients with MRH highlighting the rarity of the condition and an unmet need for treatment options that can allow sustained disease remission. It also highlights the need for a high vigilance for malignancy and autoimmune diseases.